Despite new therapies, IgAN still progresses to kidney failure in most patients. The panel reviews who is at greatest risk, which targets matter, and how hematuria fits alongside proteinuria and eGFR.
Back
Navigating Novel Pathways and Treatment Decisions in IgA Nephropathy
Nephrology experts discuss the persistent clinical burden of IgA nephropathy, the 2025 KDIGO framework, mechanisms and trial data for newly approved B-cell-targeted therapies, safety monitoring, and practical strategies for treatment selection, sequencing, and personalization.
Navigating Novel Pathways and Treatment Decisions in IgA Nephropathy
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
Experts Discuss PAH Treatment Selection and Access
2
Nalbuphine ER Rapidly Eases IPF Cough Burden, With Phil Molyneaux, MD, PhD
3
Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD
4
Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027
5